<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36310538</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal.</ArticleTitle><Pagination><StartPage>2711</StartPage><EndPage>2716</EndPage><MedlinePgn>2711-2716</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac394</ELocationID><Abstract><AbstractText>Interest in amyotrophic lateral sclerosis (ALS) biomarkers has grown exponentially over the course of the last 25 years, with great hope that they might serve as tools to facilitate the development of meaningful therapies for this otherwise inexorably progressive and invariably fatal disease. Effective use of biomarkers, however, requires an understanding of what it means for them to be 'fit-for-purpose' as well as an appreciation of the nuances of the clinical context(s) in which they will be applied. Neurofilament light chain (NfL) has emerged as a leading candidate with enormous potential to aid ALS therapy development; it is, however, also profoundly misunderstood. Within the conceptual framework of the BEST (Biomarkers, EndpointS, and other Tools) Resource, developed by the National Institutes of Health and the Food and Drug Administration in the USA, we consider the evidence supporting the use of NfL for a variety of purposes in different clinical contexts. We conclude that: (i) it may serve as a susceptibility/risk biomarker in populations at elevated risk for ALS; (ii) it has value as a prognostic biomarker when measured early in the course of established disease, empowering stratification or dynamic randomization to amplify the signal-to-noise ratio of promising therapeutics; and (iii) there is sufficient evidence to support the use of a reduction in NfL in response to an experimental therapeutic as a pharmacodynamic biomarker that may aid in phase 2 trial go/no-go decisions. Moreover, the basis for expecting that a reduction in NfL is a reasonably likely surrogate end-point (i.e. reasonably likely to predict clinical benefit-which may be more than simply survival) is nuanced, and depends on when in the course of disease the experimental therapeutic is administered.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS107027</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">neurofilament</Keyword><Keyword MajorTopicYN="N">surrogate</Keyword><Keyword MajorTopicYN="N">therapy development</Keyword></KeywordList><CoiStatement>M.B. reports remuneration for <i>ad hoc</i> consulting for Alector, Annexon, Arrowhead, Biogen, Novartis, Orphazyme and UniQure. He serves as the global academic lead for the ATLAS study (Biogen). The University of Miami has licensed intellectual property to Biogen for the design of the ATLAS study. He reports grants from the ALS Association, the Muscular Dystrophy Association, and the National Institutes of Health. He has a provisional patient pending (Determining Onset of Amyotrophic Lateral Sclerosis), and he serves as a member of the Board of Trustees for the ALS Association. J.W. reports reports grants from the National Institutes of Health. M.R.T. reports remuneration for <i>ad hoc</i> clinical advice as a member of the Endpoint Adjudication Committee for the ATLAS study (Biogen).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36310538</ArticleId><ArticleId IdType="pmc">PMC10316774</ArticleId><ArticleId IdType="doi">10.1093/brain/awac394</ArticleId><ArticleId IdType="pii">6780887</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
FDA Accepts Biogen&#x2019;s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS. News release. Biogen. Published 26 July 2022. https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-new-drug-application-and-grants-priority</Citation></Reference><Reference><Citation>
Combined FDA and Applicant Briefing Document. Published 30 March 2022. https://www.fda.gov/media/157186/download</Citation></Reference><Reference><Citation>Cudkowicz ME, Shefner JM. Regulatory Paproval in ALS; When is a single study enough? Ann Neurol. 2022;91:737&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">35478359</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Boylan K, Jeromin A, et al. . ALS biomarkers for therapy development: State of the field and future directions. Muscle Nerve. 2016;53:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718795</ArticleId><ArticleId IdType="pubmed">26574709</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.ncbi.nlm.nih.gov/books/NBK326791/ FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. In: Silver Spring (MD): Food and Drug Administration (US). Co-published by National Institutes of Health (US), Bethesda (MD); 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">27010052</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. . Design of a randomized, placebo-controlled. phase;3, trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study. Neurotherapeutics. 2022;19:1248&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">11393495</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, et al. . The combined assessment of function and survival (CAFS): A new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. . Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbrook A, Schulman S, Witt DM, et al. . Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e152S&#x2013;e184S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278055</ArticleId><ArticleId IdType="pubmed">22315259</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. . Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90:e22&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. . Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. . Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 2015;51:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270289</ArticleId><ArticleId IdType="pubmed">25288265</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol. 2013;13:153&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664389</ArticleId><ArticleId IdType="pubmed">23616620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs E, Cleveland DW. A structural scaffolding of intermediate filaments in health and disease. Science. 1998;279:514&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">9438837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Liem RK. &#x3b1;-Internexin and peripherin: Expression, assembly, functions, and roles in disease. Methods Enzymol. 2016;568:477&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">26795481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67:2013&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, et al. . Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Oeckl P, Amador MDM, et al. . A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5-6):452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">32558597</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90:870&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of pre-symptomatic ALS and phenoconversion. Ann Neurol. 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Granit V, Andersen PM, et al. . Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: A new diagnostic entity. Brain. 2022;145:3500&#x2013;3508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9586537</ArticleId><ArticleId IdType="pubmed">35594156</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Verber N, et al. . Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4:fcac029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulle S, Mellgren A, Brew BJ, et al. . CSF neurofilament protein (NFL) &#x2013; a marker of active HIV-related neurodegeneration. J Neurol. 2007;254:1026&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sormani MP, Haering DA, Kropshofer H, et al. . Blood neurofilament light as a potential endpoint in phase 2 studies in MS. Ann Clin Transl Neurol. 2019;6:1081&#x2013;1089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6562031</ArticleId><ArticleId IdType="pubmed">31211172</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras BT, Crawford TO, Finkel RS, et al. . Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6:932&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6530526</ArticleId><ArticleId IdType="pubmed">31139691</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselin F, De la Cruz E, Hirtz C, et al. . Repeated neurofilament light chain measurements did not capture riluzole therapeutic effect in amyotrophic lateral sclerosis patients. CNS Neurosci Ther. 2022;28:1532&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9437233</ArticleId><ArticleId IdType="pubmed">35751632</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla Bella E, Bersano E, Antonini G, et al. . The unfolded protein response in amyotrophic later sclerosis: Results of a phase 2 trial. Brain. 2021;144:2635&#x2013;2647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557337</ArticleId><ArticleId IdType="pubmed">33905493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>